Skip to main content
SpringerLink
Log in

Forgotten Paths in Medicine: The Case of the Low Protein Diet in Chronic Renal Failure

  • Chapter
Managing Technology in Healthcare

Part of the book series: Management of Medical Technology ((MOMT,volume 1))

Abstract

The current high and escalating costs of medical care in the U.S. has prompted a renewed interest in how new treatments become part of established medical practice. Moreover, recent findings have raised serious questions concerning the efficacy of several commonly accepted treatments.1 As the related disciplines of medical technology assessment and adoption are fairly new, there is much controversy concerning underlying mechanisms and approaches to studying these phenomena.2 Essentially, three perspectives on treatment assessment and adoption have started to emerge.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes and References

  1. For example, coronary bypass had become well-established before being properly assessed. Several recent studies have suggested that bypass may have been significantly over provided (e.g. Brook, Robert H. and Mary E. Vaiana, Appropriateness of Care: A Chart Book, Washington, D.C., George Washington University, National Health Policy Forum, 1989)

    Google Scholar 

  2. Williams, Sankey V., David B. Nash and Neil Goldfarb “Differences in Mortality From Coronary Bypass Graft Surgery at Five Teaching Hospitals” Journal of the American Medical Association V.266, No.6, 14 August 1991, pp. 810–815

    Google Scholar 

  3. Perry, Seymour “Technology Assessment: Continuing Uncertainty” New England Journal of Medicine V314, 23 January 1986, pp. 240–243

    Google Scholar 

  4. Fox, Renee C. and Judith P. Swazey The Courage to Fail: A Social View of Organ Transplants and Dialysis. Chicago: The University of Chicago Press, 1978, pp. 60–83.

    Google Scholar 

  5. Herbert, Victor Nutrition Cultism: Facts and Fictions Philadelphia: Stickley, 1980

    Google Scholar 

  6. Herbert, Victor. Nutrition Cultism Address given at White Plains Medical Center, White Plains, N.Y., 12 March 1981.

    Google Scholar 

  7. The ambiguity of criteria used to locate a treatment innovation along the experiment-therapy continuum is acknowledged by those holding this viewpoint. The search continues for indicators to help determine degrees of treatment efficacy and therapeutic value given severity of different illnesses and urgency of treatment (see Fox and Swazey, Ibid note 3, pp. 60–83

    Google Scholar 

  8. Fox, Renee C. and Judith P. Swazey, Spare Parts: Organ Replacement in American Society New York, Oxford University Press 1992, pp. 8–13

    Google Scholar 

  9. Fuchs, Victor and Alan Garber “The New Technology Assessment in Health Care” New England Journal of Medicine V323 No. 10, 6 September 1990, pp. 673–677.

    Google Scholar 

  10. Farrell, Chris. “Survival of the fittest technologies” New Scientist, February 6, 1993, pp. 35–39.

    Google Scholar 

  11. Aaron, Henry Serious and Unstable Condition: The US Medical System. Washington, D.C., The Brookings Institution, 1991

    Google Scholar 

  12. Wasley, Terree P. What Has Government Done to Our Health Care? Washington, Cato Institute, 1992.

    Google Scholar 

  13. Dutton, Diana B. Worse Than the Disease: Pitfalls of Medical Progress Cambridge, Cambridge University Press, 1988

    Google Scholar 

  14. Freidson, Elliot Professional Powers: A Study in the Institutionalization of Formal Knowledge Chicago, University of Chicago Press, 1986

    Google Scholar 

  15. Freidson, Elliot Profession of Medicine: A Study of the Sociology of Applied Knowledge. New York, Dodd, Mead & Company 1988.

    Google Scholar 

  16. Connor, K. R. “Strategies for Product Cannibalization” Strategic Management Journal, Vol. 9, Summer 1988, pp. 9–26.

    Google Scholar 

  17. Garud, Raghu. and Michael.A. Rappa. “A socio-cognitive model of technology evolution” Organization Science, vol. 5, no. 3, pp 344–362, 1994

    Google Scholar 

  18. Garud, Raghu and David Ahlstrom. “Technology Assessment: A Socio-Cognitive Perspective” Forthcoming in Journal of Engineering and Technology Management

    Google Scholar 

  19. Powell, Walter W. “Expanding the Scope of Institutional Analysis” in Powell, Walter W. and Paul J. DiMaggio (eds.) The New Institutionalism in Organizational Analysis Chicago, University of Chicago Press, 1991, 183–203.

    Google Scholar 

  20. Economic historians Brian Arthur and Paul David have discussed the surprising way in which minor historical events can set a technology on a specific path that is not guaranteed to be efficient, nor is easily altered. An example that David cites is the QWERTY keyboard. Although the QWERTY design is less efficient than competing keyboard arrangements, too much is invested in the QWERTY for manufacturers or users to easily switch to newer designs. Moreover, positive feedback, where the more a technology is adopted the more it is improved, serve to reinforce a given technological path (See Paul David “Clio and the Economics of QWERTY”, Economic History, V.75, 1985, pp. 227–332)

    Google Scholar 

  21. Arthur, Brian. “Self-reinforcing mechanisms in economics”. In P. Anderson et al. (eds.), The Economy as an Evolving Complex System, Reading, MA, Addison-Wesley, 1988;

    Google Scholar 

  22. Scott, W. Richard. “Unpacking Institutional Arguments” in Powell, Walter W. and Paul J. DiMaggio (eds.) Ibid note 9, pp. 164–182

    Google Scholar 

  23. See Wennberg, John “Which Way is Right?” New England Journal of Medicine V314, 30 January 1986, pp. 310–311

    Google Scholar 

  24. Wasserstein, Alan G. “Changing Patterns of Medical Practice: Protein Restriction for Chronic Renal Failure” Annals of Internal Medicine V119, 1993, pp. 79–85.

    Google Scholar 

  25. Fombrun, Charles J. “Structural Dynamics within and between Organizations” Administrative Science Quarterly, V31, 1986, pp. 403–421

    Google Scholar 

  26. This position is consistent with the position taken by Van de Ven and Garud, who suggest that to understand the evolution of new industries, we must examine multiple arenas of action that include the instrumental, resource procurement, and the institutional. See Van de Ven and Garud, “A framework, for understanding the emergence of new industries”, in Rosenbloom, R.S. and Burgelman, R. A. Research on technological innovation, management and policy, Vol. 4, pp. 195–225, 1989

    Google Scholar 

  27. Scott, Ibid note 11

    Google Scholar 

  28. Rosenberg, N. Inside the Black Box: Technology and Economics, Cambridge University Press, Cambridge, 1982.

    Google Scholar 

  29. Dosi, G. “Technological Paradigms and Technological Trajectories”, Research Policy, 11, pp. 147–162, 1982.

    Google Scholar 

  30. Other concepts that are relevant to an understanding of the concept of technological trajectory include: technological style (see Hughes, T.P. Networks of Power: Electrification in Western Society, 1880–1930 Baltimore, Johns Hopkins University Press, 1983)

    Google Scholar 

  31. technological tradition (e.g. Constant, E.W. The Origins of the Turbojet Revolution Baltimore, Johns Hopkins University Press, 1980

    Google Scholar 

  32. Laudan, R., ed. The Nature of Technological Knowledge: Are Models of Scientific Change Relevant? 1984)

    Google Scholar 

  33. research tradition (Laudan, Larry. 1977. Progress and its Problems: toward a theory of scientific growth. Berkeley: University of California Press)

    Google Scholar 

  34. technological paradigm (Dosi, G. “Technological paradigms and technological trajectories: A suggested interpretation of the determinants and directions of technical change” Research Policy 11, 1982, pp. 147–162

    Google Scholar 

  35. Dosi, G. Technological Change and Industrial Transformation London, MacMillan, 1984

    Google Scholar 

  36. Gutting, G. “Paradigms, revolutions, and technology” in The Nature of Technological Knowledge: Are Models of Scientific Change Relevant? Dordrecht, Reidel, 1984, pp. 47–65

    Google Scholar 

  37. van den Belt, H. and Rip, A. “The Social Construction of Bakelite: Toward a Theory of Invention” in Bijker, W. Hughes, T. and T. Pinch (eds.) The Social Construction of Technological Systems Cambridge, MA., MIT Press, 1987, pp. 135–158)

    Google Scholar 

  38. technological orientation complex (see Weingart, P. “The structure of technological change: Reflections on a sociological analysis of technology” in Laudan, R. (ed.) The Nature of Technological Knowledge: Are Models of Scientific Change Relevant? Dordrecht, Reidel, 1984, pp. 115–142)

    Google Scholar 

  39. technological regime (Nelson, R. and S. Winter “In Search of a Useful Theory of Innovation” Research Policy 6, 1977, pp.36–76). Rather than define each of the terms, we direct the reader to The Social Construction of Technological Systems by Bijker, Hughes and Pinch (1987) as an efficient way to understand these concepts in technology studies.

    Google Scholar 

  40. Dosi, Ibid note 17

    Google Scholar 

  41. Nelson, Richard and Stanley G. Winter, An evolutionary theory of economic change, Cambridge, MA, Harvard University Press 1982.

    Google Scholar 

  42. Chronic renal failure afflicts well over 100 thousand Americans and perhaps millions worldside, annual treatment costs have reached nearly seven billion dollars in the US alone (see U.S. Renal Data System 1991 and 1993 Annual Reports Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Renal failures). The cost of the end-stage renal failure program (the federal program that pays for dialysis and transplantation) has risen at an annualized rate of roughly 20 percent per year since the program’s inception in 1972 (Fox and Swazey, 1978: 349; Ibid note 3).

    Google Scholar 

  43. Giovannetti, Sergio. “Dietary Treatment of Chronic Renal Failure: Why Is It Not Used More Frequently?” Nephron. V40, 1985, pp. 1–12

    Google Scholar 

  44. Giovannetti, Ibid note 21

    Google Scholar 

  45. Mitch, William and MacKenzie Walser “Nutritional Therapy of the Uremic Patient” in Brenner, B. and Rector, F. (eds.) The Kidney. Philadelphia: W.B. Saunders, 1991, pp. 2186–2222

    Google Scholar 

  46. Brenner, B. and Rector, F. Ibid note 22.

    Google Scholar 

  47. Fox and Swazey, Ibid note 3

    Google Scholar 

  48. see Thomas, Lewis. The Lives of a Cell New York, Viking Press, 1974 especially pp. 31–36.

    Google Scholar 

  49. U.S. Renal Data System 1994 Annual Reports Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Renal failures, p. 10.

    Google Scholar 

  50. Werth, Barry The Billion Dollar Molecule: One Company’s Quest for the Perfect Drug New York: Simon and Schuster, 1994.

    Google Scholar 

  51. Giovannetti, S. (ed.) Nutritional Treatment of Chronic Renal Failure Boston, Kluwer, 1989

    Google Scholar 

  52. Walser, MacKenzie. “Ketoacids in the Treatment of Uremia”. Clinical Nephrology 3: 1975, 180–186

    Google Scholar 

  53. Mitch, William and MacKenzie Walser “Nutritional Therapy of the Uremic Patient” in Brenner, B. and Rector, F. (eds.) The Kidney. Philadelphia: W.B. Saunders, 1991, pp. 2186–2222.

    Google Scholar 

  54. Giordano, C. “Use of Exogenous and Endogenous Urea for Protein Synthesis in Normal and Uremic Subjects” Journal of Laboratory and Clinical Medicine V62, 1963, pp. 231–236

    Google Scholar 

  55. Giovannetti, Sergio and Q. Maggiore “A Low-Nitrogen Diet with Proteins of High Biological Value for Severe Chronic Uremia” Lancet, V1, 9 May 1964, pp. 1000–1004

    Google Scholar 

  56. Mitch & Walser, Ibid note 22

    Google Scholar 

  57. Graham, Thomas “The Bakerian Lecture — On Osmotic Force” Philosophical Transactions Royal Society of London V144, 1854, pp. 177–228.

    Google Scholar 

  58. Abel, J., L.G. Rowntree and B.B. Turner “On the Removal of Diffusible Substances from the Circulating Blood of Living Animals by Dialysis” Journal of Pharmacological Experimental Therapy V5, 1914, pp. 275–316.

    Google Scholar 

  59. Kolff, Willem (1965) “First Clinical Experience with the Artificial Kidney” Annals of Internal Medicine V62, No. 3, 608–619.

    Google Scholar 

  60. McBride, Patrick Genesis of the Artificial Kidney Deerfield, IL, Travenol Laboratories, Inc., 1979.

    Google Scholar 

  61. Fox and Swazey, Ibid note 3

    Google Scholar 

  62. Fox and Swazey, Ibid note 3

    Google Scholar 

  63. Rettig, Richard A. (1976) “The Policy of Debate on Patient Care Financing for Victims of End-Stage Renal Disease” Law & Contemporary Problems. V40/4, Autumn, 196–230.

    Google Scholar 

  64. Starr, Paul (1974) The Discarded Army: Veterans after Vietnam. New York: Charter House.

    Google Scholar 

  65. Rettig, Ibid note 37, p. 210.

    Google Scholar 

  66. Freidson, 1986, Ibid note 7, p.2.

    Google Scholar 

  67. Fox and Swazey, Ibid note 3

    Google Scholar 

  68. Thomas, Ibid note 25; Bricker, Neal, M.D. Personal Communication December, 1991.

    Google Scholar 

  69. Medical World News (1966) “Renal Group Eases Policy on Dialysis” April 8, p83; Rettig, Richard A. “Valuing Lives: The Policy Debate on Patient Care Financing for Victims of End-stage Renal Disease” Rand Paper Series, 1976.

    Google Scholar 

  70. Rettig, Richard A. (1991) “Origins of the Medicare Renal Failure Entitlement: The Social Security Amendments of 1972” in Hanna, Kathi E. (ed.) Biomedical Politics Washington: National Academy Press, 176–208.

    Google Scholar 

  71. Fox and Swazey, Ibid note 3.

    Google Scholar 

  72. Rettig, Ibid note 37

    Google Scholar 

  73. Fox and Swazey, Ibid note 3; pp. 348–349

    Google Scholar 

  74. Rettig, Ibid note 43.

    Google Scholar 

  75. Fox and Swazey, Ibid note 3; p. 349.

    Google Scholar 

  76. Kolata, G. 1980. “NMC thrives selling dialysis”. Science. 208/25 April, 1980, pp. 379–381.

    Google Scholar 

  77. p. 379.

    Google Scholar 

  78. Kolata Ibid note 48

    Google Scholar 

  79. Relman, A. and D. Rennie “Treatment of End-stage Renal Disease: Free but not equal” The New England Journal of Medicine 303/17, 1980, pp. 996–998.

    Google Scholar 

  80. Kolata, Ibid note 48.

    Google Scholar 

  81. Fox and Swazey, Ibid note 3: p. 363.

    Google Scholar 

  82. Kolata, Ibid note 48

    Google Scholar 

  83. Rettig, Ibid note 36.

    Google Scholar 

  84. Kolata, Ibid note 48.

    Google Scholar 

  85. Today the discrepancy may be even more pronounced: $6,000–8,000 versus $31,000 for in-clinic dialysis (USRDS, 1992). Starr, Paul (1982) The Social Transformation of American Medicine. New York: Basic Books, Inc., see pp. 442–443.

    Google Scholar 

  86. Bovbjerg, Randall R., Philip J. Held and Louis H. Diamond (1987) “Provider-Patient Relations and Treatment Choice in the Era of Fiscal Incentives: The Case of the End-stage Renal Disease Program” The Milbank Quarterly. V65, No 2, 177–202.

    Google Scholar 

  87. Starr, Paul (1982) The Social Transformation of American Medicine. New York: Basic Books, Inc., see pp. 442–443 The outcome data on home dialysis was and has continued to be comparable to those of in-clinic dialysis (USRDS, 1994, Ibid note 20).

    Google Scholar 

  88. Daniels, R. 1991. “Legislation in the American dialysis industry: Some considerations about monopoly power in renal care.” American Journal of Economics and Sociology. 15/2: pp. 223–242; USRDS Ibid note 19

    Google Scholar 

  89. Barnett, Andy H., T. Randolph Beard and David Kaserman “Inefficient Pricing Can Kill: The Case of Dialysis Industry Regulation” Southern Economic Journal V60/2 October 1993, pp. 393–404. NMC has continued to grow at a healthy clip. Annual revenues were $316 million in 1985, and they are estimated today to be $1 billion. (Standard and Poor Register of Corporations, Directors and Executives. New York: Standard and Poor, 1993: V1).

    Google Scholar 

  90. Kolata, Ibid note 48, p. 381.

    Google Scholar 

  91. Bovbjerg et al., Ibid note 55.

    Google Scholar 

  92. Urban Institute Survey of Dialysis Institutions (SODI) (Random National Survey of Dialysis Units) Washington, D.C., Urban Institute, 1985.

    Google Scholar 

  93. Greenspan, R.E. (1981) “The High Price of Federally Regulated Hemodialysis” Journal of the American Medical Association. V246, No. 17, October, pp.1901–1911.

    Google Scholar 

  94. Barnett et al., Ibid note 57; Ben Burton, long time head of the of the NIH contract program concerned with chronic renal failure also suggested the importance of economics in guiding the specialty’s technological emphasis.

    Google Scholar 

  95. Eggers, P.W. “Health Care Policies/Economics of the Geriatric Renal Population” American Journal of Renal failure 15/5, 1990, pp.375–383.

    Google Scholar 

  96. Altman, Lawrence “Studies Are Grim on Dialysis Outlook” The New York Times, National edition, January 5, 1994, p. A12.

    Google Scholar 

  97. Novello, A. “Ethical, Social, and Financial Aspects of End-stage Renal Disease” in B. Brenner and F. Rector Ibid note 22.

    Google Scholar 

  98. USRDS, 1991, Ibid note 20, p. 10.

    Google Scholar 

  99. Altman, Ibid note 64.

    Google Scholar 

  100. Fox and Swazey, Ibid note 3.

    Google Scholar 

  101. Starzl, Thomas E. “The Development of Clinical Renal Transplantation” American Journal of Renal failures. V16, No 6, December, 1990, pp.548–556

    Google Scholar 

  102. Starzl, Ibid note 69.

    Google Scholar 

  103. Starzl, Ibid note 69.

    Google Scholar 

  104. Starzl, Ibid note 69. The new immunosuppressant, FK506 (prograf) was approved by FDA in 1994 and has shown some promise in reducing the morbidity and rejection rates that have plagued transplanation.

    Google Scholar 

  105. Rettig, R. 1989 “The Politics of Organ Transplantation: A Parable of Our Time” Journal of Health Politics, Policy and Law V14/1 Spring 191–227.

    Google Scholar 

  106. Starzl, Thomas. 1992. The Puzzle People: Memoirs of a Transplant Surgeon Pittsburgh, PA, University of Pittsburgh Press.

    Google Scholar 

  107. USRDS, 1991, Ibid note 20

    Google Scholar 

  108. Williams, G.M., J.F Burdick, and K. Solez (eds) Kidney Transplant Rejection New York, Marcel Dekker, 1986.

    Google Scholar 

  109. Rettig, Ibid note 73., p. 195.

    Google Scholar 

  110. Kutner, Nancy G. 1982 “Cost-Benefit Issues in US National Health Legislation: The Case of the End-stage Renal Disease Program” Social Problems V30, 51–64.

    Google Scholar 

  111. Rettig, Ibid note 73.

    Google Scholar 

  112. Starzl, ibid note 74.

    Google Scholar 

  113. Rettig, Ibid note 73.

    Google Scholar 

  114. Fox and Swazey, 1992, Ibid note 14.

    Google Scholar 

  115. That figure can be found in respected publications such The New York Times (see Kolata, Gina. 1990. “American Transplant Pioneers Win Nobel Prize in Medicine” The New York Times. October 9, C3) as well as scientific publications. For instance the 90 percent transplantation success figure was commonly quoted in the recent book-length study by the National Academy of Science’s Institute of Medicine on Renal failure

    Google Scholar 

  116. (see Rettig, Richard and Levinsky, Norm. 1991. The Federal Government and End-stage Renal Disease. Washington, Institute of Medicine).

    Google Scholar 

  117. Kutner, Ibid note 78

    Google Scholar 

  118. Daniels, Ibid note 57.

    Google Scholar 

  119. Williams, Ibid note 72;  Paller, M.S. “Cyclosporine nephrotoxicity and the role of cyclosporine in living-related donor transplantation” American Journal of Renal failure V16/5, 1990 pp. 414–416.

    Google Scholar 

  120. Werth, Barry “The Drug that Works in Pittsburgh” The New York Times Magazine, September 30, 1990, pp. 35, 58–60.

    Google Scholar 

  121. Kutner, Nancy G (1990) “Issues in the Application of High Cost Medical Technology: The Case of Organ Transplantation” in Conrad, Peter and Rochelle Kern (eds.) The Sociology of Health & Illness: Critical Perspectives New York: St. Martin’s Press, 358–372.

    Google Scholar 

  122. MEDLINE (Database Online). 1989-. Bethesda, MD: National Library of Medicine. Research activity is determined using article counts from MEDLINE.There are roughly four times as many dialysis patients as transplant patients.

    Google Scholar 

  123. Giovannetti, Sergio. (1985) “Dietary Treatment of Chronic Renal Failure: Why Is It Not Used More Frequently?” Nephron. V40, 1–12.

    Google Scholar 

  124. Bright, Richard Reports of Medical Cases Selected with a View of Illustrating the Symptoms and Cure of Disease by a Reference to Morbid anatomy London, Longman, 1827

    Google Scholar 

  125. Bright, Richard “Cases and Observations Illustrative of Renal Disease Accompanied with Secretion of Albuminous Urine” Guy’s Hospital Reports V1, 1836, pp.338–379.

    Google Scholar 

  126. Beale, Lionel S. Renal failures. Urinary Deposits, and Calculous Disorders: Their Nature and Treatment. Philadelphia: Linds ay and Blakiston, 1869.

    Google Scholar 

  127. Folin, Otto “Laws Governing the Chemical Composition of Urine” American Journal of Physiology, V13, 1905.

    Google Scholar 

  128. Bergstrom, J. “Discovery and Rediscovery of Low Protein Diet” Clinical Nephrology 21, 1984. 29–35.

    Google Scholar 

  129. Addis, Thomas Glomerular Nephritis: Diagnosis and Treatment New York, MacMillan, 1948.

    Google Scholar 

  130. Addis, Ibid note 94.

    Google Scholar 

  131. McBride, Patrick Genesis of the Artificial Kidney Deerfield, IL, Travenol Laboratories, Inc., 1979.

    Google Scholar 

  132. Giordano, Ibid note 28.

    Google Scholar 

  133. Giovannetti and Maggiore, Ibid note 28.

    Google Scholar 

  134. Giovannetti, Sergio, Personal Communication, 1992.

    Google Scholar 

  135. Harum, Peggy Nutritional Consultant to the Department of Nephrology, University of Miami School of Medicine, Personal Communication, May 1992.

    Google Scholar 

  136. 101. Giovannetti, Ibid note 99.

    Google Scholar 

  137. Giovannetti, Ibid note 99; France, George and Francesco Taroni “Economic Appraisal of Health Technology in Italy” in Drummond, M.F. Economic Appraisal of Health Technology in the European Community Oxford, Oxford University Press, 1987, 209–222.

    Google Scholar 

  138. Medline, Ibid note 88.

    Google Scholar 

  139. Walser, Ibid note 26.

    Google Scholar 

  140. Klahr, Saulo; Levey, Andrew S.; Beck, Gerald J.; Caggiula, Arlene; Hunsicker, Lawrence; Kusek, John W. and Gary Striker “The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease” The New England Journal of Medicine V330/13, March 31, 1994, pp. 877–884.

    Google Scholar 

  141. Levey, Andrew. Personal Communication; Walser, MacKenzie. 1995.

    Google Scholar 

  142. As DPR is an early stage intervention treatment, it is best applied to chronic kidney patients early in their disease much the way carbohydrate restricted diet is provided for new diabetes patients. Complete care would likely include a DPR regimen administered directly by a nephrologist and a renal dietitian, and would include regular blood tests for creatinine and glomerular filtration rate to determine kidney function over time. Renal dietitians would train patients in locating and preparing low protein and low phosphorous meals. Careful monitoring of the patient continues after entry onto dialysis.

    Google Scholar 

  143. A lively discussion is continuing regarding the interpretation of the MDRD and the recommendations that can be made based on the findings Mitch, William. Personal communication, 1996).

    Google Scholar 

  144. Walser has produced data that show patients who have been on a DPR regimen enter dialysis healthier than a control group (eg. Walser, MacKenzie. 1993. ‘‘Does prolonged protein restriction preceding dialysis lead to protein malnutrition at the onset of dialysis” Kidney International V44/5, November: 1139–1144).

    Google Scholar 

  145. Fox and Swazey, Ibid note 3.

    Google Scholar 

  146. Starzl, Thomas; R. Weil, and C.W. Putnam “Modern Trends In Kidney Transplantation” Transplantation Proceedings V9, March 1977, pp. 1–8; A similar pattern is emerging in the artificial heart area which is now seen as more of a stepping stone to transplantation as opposed to a permanent replacement.

    Google Scholar 

  147. Giovannetti, Ibid note 99.

    Google Scholar 

  148. That “shortcoming” of DPR was addressed by the recently completed Modification of Diet in Renal Disease (MDRD)—a ten year prospectively conducted study, see Klahr et al., Ibid note 105

    Google Scholar 

  149. Plough, Alonzo L. Borrowed Time: Artificial Organs and the Politics of Extending Lives. Philadelphia: Temple University Press, 1986.

    Google Scholar 

  150. Rettig, Ibid note; Scribner, Belding “A Personalized History of Chronic Hemodialysis” American Journal of Renal failure V16/6 December, 1990, pp. 511–519.

    Google Scholar 

  151. Walser, MacKenzie. 1975. “Ketoacids in the Treatment of Uremia”. Clinical Nephrology 3: 180–186

    Google Scholar 

  152. Walser, MacKenzie; William Mitch and V.U. Collier “The Effect of Nutritional Therapy on the Course of Chronic Renal Failure” Clinical Nephrology, V11 1979, p. 66–74

    Google Scholar 

  153.  Neuringer, J.R. and Levey, A.S. 1994. “Strategies to slow the progression of renal disease” Seminars in Nephrology V14/3, May: 261–273.

    Google Scholar 

  154. McGinnis 1988–1989.

    Google Scholar 

  155. Thomas, Ibid note 25.

    Google Scholar 

  156. Thomas, Ibid note 25.

    Google Scholar 

  157. Thomas, Ibid note 25.

    Google Scholar 

  158. Eggers, Ibid note 62.

    Google Scholar 

  159. Thomas, Lewis International Journal of Technology Assessment V1, January 1987, p. 5.

    Google Scholar 

  160. Rettig, Ibid note 37

    Google Scholar 

  161. Bricker, Ibid note 39.

    Google Scholar 

  162. Callahan, Daniel What Kind of Life: The Limits of Medical Progress. New York: Simon and Schuster, 1990.

    Google Scholar 

  163. Callahan, Ibid note 125, p 65.

    Google Scholar 

  164. Risjord, Mark “Relativism and the Social Scientific Study of Medicine” The Journal of Medicine and Philosophy 18/2 April, 1993, pp. 195–212.

    Google Scholar 

  165. Constant, E. W. (1980) The origins of the turbojet revolution. Baltimore: John Hopkins University Press.

    Google Scholar 

  166. Risjord, Ibid note 127.

    Google Scholar 

  167. Sullivan, Mark D. “Placebo Controls and Epistemic Control in Othodox Medicine” The Journal of Medicine and Philosophy 18/2 April, 1993, pp. 213–231.

    Google Scholar 

  168. Sullivan, Ibid note 130.

    Google Scholar 

  169. Callahan, Ibid note 125.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leonard N. Stern School of Business, New York University, USA

    David Ahlstrom & Raghu Garud

Authors
  1. David Ahlstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raghu Garud
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Eliezer Geisler Ori Heller

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Ahlstrom, D., Garud, R. (1996). Forgotten Paths in Medicine: The Case of the Low Protein Diet in Chronic Renal Failure. In: Geisler, E., Heller, O. (eds) Managing Technology in Healthcare. Management of Medical Technology, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1415-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1415-8_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8614-1

  • Online ISBN: 978-1-4613-1415-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation